Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/15724
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.
Hernández-Jiménez, Macarena | Martín-Vílchez, Samuel | Ochoa, Dolores | Mejía-Abril, Gina | Román, Manuel | Camargo-Mamani, Paola | Luquero-Bueno, Sergio | Jilma, Bernd | Moro, María A | Fernández, Gerónimo | Piñeiro, David | Ribó, Marc | González, Victor M | Lizasoain, Ignacio | Abad-Santos, Francisco
Mol Ther Nucleic Acids. 2022 Mar 9;28:124-135
ApTOLL is an aptamer that antagonizes Toll-like receptor 4 and improves functional outcomes in models of ischemic stroke and myocardial infarction. The aim of this study was to characterize the safety and pharmacokinetics of ApTOLL in healthy volunteers. A first-in-human dose-ascending, randomized, placebo-controlled phase I clinical trial to assess safety and pharmacokinetics of ApTOLL (30-min infusion intravenously) was performed in 46 healthy adult male volunteers. The study was divided into two parts: part A included seven single ascending dose levels, and part B had one multiple dose cohort. Safety and pharmacokinetic parameters were evaluated. No serious adverse events or biochemistry alterations were detected at any dose nor at any administration pattern studied. Maximum concentration was detected at the end of the infusion and mean half-life was 9.3 h. Interestingly, exposure increased in the first four levels receiving doses from 0.7 mg to 14 mg (AUC of 2,441.26 h∗ng/mL to 23,371.11 h∗ng/mL) but remained stable thereafter (mean of 23,184.61 h∗ng/mL after 70 mg). Consequently, the multiple dose study did not show any accumulation of ApTOLL. These results show an excellent safety and adequate pharmacokinetic profile that, together with the efficacy demonstrated in nonclinical studies, provide the basis to start clinical trials in patients.
- Investigación > IIS > IRYCIS - Instituto Ramón y Cajal de Investigación Sanitaria (Madrid) > IIS - Artículos
- Investigación > IIS > IIS-PRINCESA - Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (Madrid) > IIS - Artículos
- Investigación > IIS > i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid) > IIS - Artículos
- Investigación > CNIC > Grupos de investigación > CNIC - Artículos
Files in this item
- First in human phase Mol Ther ...